JP2017513852A - Ｃ型肝炎ウイルスの強力及び選択的な阻害剤 - Google Patents

Ｃ型肝炎ウイルスの強力及び選択的な阻害剤 Download PDF

Info

Publication number
JP2017513852A
JP2017513852A JP2016562874A JP2016562874A JP2017513852A JP 2017513852 A JP2017513852 A JP 2017513852A JP 2016562874 A JP2016562874 A JP 2016562874A JP 2016562874 A JP2016562874 A JP 2016562874A JP 2017513852 A JP2017513852 A JP 2017513852A
Authority
JP
Japan
Prior art keywords
compound
alkyl
hcv
aryl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016562874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513852A5 (enExample
Inventor
ジェイ． コーツ，スティーブン
ジェイ． コーツ，スティーブン
アンソニー ウィタカー，リチャード
アンソニー ウィタカー，リチャード
ロサリオ マクブレイヤー，タマラ
ロサリオ マクブレイヤー，タマラ
シ，ジュンシン
アンブラード，フランク
チャン，ホンワン
チョウ，ロンフー
エフ． シナジ，レイモンド
エフ． シナジ，レイモンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Cocrystal Pharma Inc
Original Assignee
Emory University
Cocrystal Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University, Cocrystal Pharma Inc filed Critical Emory University
Publication of JP2017513852A publication Critical patent/JP2017513852A/ja
Publication of JP2017513852A5 publication Critical patent/JP2017513852A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2016562874A 2014-04-15 2015-04-15 Ｃ型肝炎ウイルスの強力及び選択的な阻害剤 Pending JP2017513852A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461980016P 2014-04-15 2014-04-15
US61/980,016 2014-04-15
PCT/US2015/025903 WO2015160907A2 (en) 2014-04-15 2015-04-15 Potent and selective inhibitors of hepatitis c virus

Publications (2)

Publication Number Publication Date
JP2017513852A true JP2017513852A (ja) 2017-06-01
JP2017513852A5 JP2017513852A5 (enExample) 2018-05-31

Family

ID=54324704

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016562874A Pending JP2017513852A (ja) 2014-04-15 2015-04-15 Ｃ型肝炎ウイルスの強力及び選択的な阻害剤

Country Status (14)

Country Link
US (1) US9926295B2 (enExample)
EP (1) EP3131892A4 (enExample)
JP (1) JP2017513852A (enExample)
KR (1) KR20170002407A (enExample)
CN (1) CN106661004A (enExample)
AU (1) AU2015247706A1 (enExample)
BR (1) BR112016023833A2 (enExample)
CA (1) CA2945514A1 (enExample)
IL (1) IL248318A0 (enExample)
MX (1) MX2016013434A (enExample)
PH (1) PH12016502039A1 (enExample)
RU (1) RU2016144076A (enExample)
SG (1) SG11201608587QA (enExample)
WO (1) WO2015160907A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021523129A (ja) * 2018-05-09 2021-09-02 コクリスタル ファーマ, インコーポレイテッドCocrystal Pharma, Inc. Ｈｃｖを治療するための併用療法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN109456375B (zh) * 2018-12-11 2019-10-22 枣庄学院 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511833A (ja) * 2008-02-13 2011-04-14 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
WO2012027712A2 (en) * 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
WO2012048421A1 (en) * 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
JP2013514359A (ja) * 2009-12-16 2013-04-25 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1005401A2 (pt) * 2009-02-06 2019-04-02 Rfs Pharma, Llc pro-farmácos de purina nucleosídeo monofosfato para o tratamento de câncer e infecções virais
AU2011323658A1 (en) * 2010-11-01 2013-05-23 Genoscience Pharma Novel specific HCV NS3 protease inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511833A (ja) * 2008-02-13 2011-04-14 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
JP2013514359A (ja) * 2009-12-16 2013-04-25 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
WO2012027712A2 (en) * 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
WO2012048421A1 (en) * 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021523129A (ja) * 2018-05-09 2021-09-02 コクリスタル ファーマ, インコーポレイテッドCocrystal Pharma, Inc. Ｈｃｖを治療するための併用療法
JP7381493B2 (ja) 2018-05-09 2023-11-15 コクリスタル ファーマ，インコーポレイテッド Ｈｃｖを治療するための併用療法

Also Published As

Publication number Publication date
SG11201608587QA (en) 2016-11-29
BR112016023833A2 (pt) 2017-10-10
IL248318A0 (en) 2016-11-30
WO2015160907A2 (en) 2015-10-22
AU2015247706A1 (en) 2016-10-27
WO2015160907A3 (en) 2016-12-01
MX2016013434A (es) 2017-03-03
US20170029407A1 (en) 2017-02-02
CN106661004A (zh) 2017-05-10
EP3131892A2 (en) 2017-02-22
KR20170002407A (ko) 2017-01-06
PH12016502039A1 (en) 2017-01-09
CA2945514A1 (en) 2015-10-22
US9926295B2 (en) 2018-03-27
EP3131892A4 (en) 2017-09-20
RU2016144076A (ru) 2018-05-16

Similar Documents

Publication Publication Date Title
US9932326B2 (en) Potent and selective inhibitors of hepatitis C virus
US11859014B2 (en) Peptidomimetics for the treatment of Norovirus infection
JP5611959B2 (ja) Ｃ型肝炎ウイルス阻害剤
US9040479B2 (en) HCV NS3 protease inhibitors
JP5826269B2 (ja) Ｈｃｖ阻害剤としてのヘテロ−二環式誘導体
US9926295B2 (en) Potent and selective inhibitors of hepatitis C virus
JP5828903B2 (ja) 新規特異的ｈｃｖ ｎｓ３プロテアーゼ阻害剤
US20170037078A1 (en) 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX2013000906A (es) Compuestos de tiofeno 2, 3, 5-trisustituidos y usos de los mismos.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180413

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180424

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180706

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190123